CoChat

Solid tumors provide niche-specific conditions that lead to preferential growth of Salmonella

Open access
Silva-Valenzuela, Cecilia A., Desai, Prerak T., Molina-Quiroz, Roberto C., Pezoa, David, Zhang, Yong, Porwollik, Steffen, Zhao, Ming, Hoffman, Robert M., Contreras, Inés, Santiviago, Carlos A., McClelland, Michael · 2016 · Oncotarget
Cited by 44

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

// Cecilia A. Silva-Valenzuela 1, 2, 3 , Prerak T. Desai 1 , Roberto C. Molina-Quiroz 2, 4 , David Pezoa 2 , Yong Zhang 5 , Steffen Porwollik 1 , Ming Zhao 5 , Robert M. Hoffman 5, 6 , Inés Contreras 2 , Carlos A. Santiviago 2 , Michael McClelland 1 1 Department of Microbiology and Molecular Genetics, University of California, Irvine, CA, USA 2 Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile 3 Current address: Department of Molecular Biology and Microbiology, Tufts University, Boston, MA, USA 4 Current address: Center for Adaptation Genetics and Drug Resistance, Tufts University, Boston, MA, USA 5 AntiCancer, Inc., San Diego, CA, USA 6 Department of Surgery, University of California, San Diego, CA, USA Correspondence to: Carlos A. Santiviago, e-mail: csantiviago@ciq.uchile.cl Michael McClelland, e-mail: mmcclell@uci.edu Keywords: Salmonella Typhimurium, ethanolamine, high-throughput, mammary cancer, 4T1 Received: November 4, 2015 Accepted: April 10, 2016 Published: April 28, 2016 ABSTRACT Therapeutic attenuated strains of Salmonella Typhimurium target and eradicate tumors in mouse models. However, the mechanism of S . Typhimurium for tumor targeting is still poorly understood. We performed a high-throughput screening of single-gene deletion mutants of S . Typhimurium in an orthotopic, syngeneic murine mammary model of breast cancer. The mutants under selection in this system were classified into functional categories to identify bacterial processes involved in Salmonella accumulation within tumors. Niche-specific genes involved in preferential tumor colonization were identified and exemplars were confirmed by competitive infection assays. Our results show that the chemotaxis gene cheY and the motility genes motAB confer an advantage for colonization of Salmonella within orthotopic syngeneic breast tumors. In addition, eutC , a gene belonging to the ethanolamine metabolic pathway, also confers an advantage for Salmonella within tumors, perhaps by exploiting either ethanolamine or an alternative nutrient in the inflamed tumor environment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.9071

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 81

  1. Lambin, 2003, Modulation of cell death in the tumor microenvironment, Semin Radiat Oncol, 13, 31, 10.1053/srao.2003.50004 · DOI
  2. Zhao, 2014, Methods for the development of tumor-targeting bacteria, Expert Opin Drug Discov, 9, 741, 10.1517/17460441.2014.916270 · DOI
  3. Oelschlaeger, 2010, Bacteria as tumor therapeutics?, Bioengineered Bugs, 1, 146, 10.4161/bbug.1.2.11248 · DOI
  4. McCormick, 2010, Targeting tumors with- potential for therapy, Oncotarget, 1, 721, 10.18632/oncotarget.206 · DOI
  5. Chakravortty, 2012, serovars Typhimurium and Typhi as model organisms: revealing paradigm of host-pathogen interactions, Virulence, 3, 377, 10.4161/viru.21087 · DOI
  6. Hoffman, 2012, Bugging tumors, Cancer Discov, 2, 588, 10.1158/2159-8290.CD-12-0227 · DOI
  7. Forbes, 2008, Tumor-targeting attenuatedTyphimurium accumulates within therapeutically-resistant microenvironments adjacent to tumor necrosis, J Am Coll Surgeons, 207, S101, 10.1016/j.jamcollsurg.2008.06.259 · doi:10.1016/j.jamcollsurg.2008.06.259
  8. Smooker, 2015, Live-attenuated bacterial vectors: tools for vaccine and therapeutic agent delivery, Vaccines (Basel), 3, 940, 10.3390/vaccines3040940 · DOI
  9. Blagosklonny, 2003, Matching targets for selective cancer therapy, Drug Discov Today, 8, 1104, 10.1016/S1359-6446(03)02806-X · DOI
  10. Blagosklonny, 2003, Tissue-selective therapy of cancer, Br J Cancer, 89, 1147, 10.1038/sj.bjc.6601256 · DOI
  11. Theys, 2007, Potential and limitations of bacterial-mediated cancer therapy, Front Biosci, 12, 3880, 10.2741/2357 · DOI
  12. Bermudes, 1997, Tumor-targetedas a novel anticancer vector, Cancer Res, 57, 4537
  13. Hoffman, 2011, Tumor-seekingamino acid auxotrophs, Curr Opin Biotechnol, 22, 917, 10.1016/j.copbio.2011.03.009 · DOI
  14. Forbes, 2011, In tumorsmigrate away from vasculature toward the transition zone and induce apoptosis, Cancer Gene Ther, 18, 457, 10.1038/cgt.2011.10 · DOI · Paper page
  15. Weiss, 2011, Biofilm formation byserovar Typhimurium colonizing solid tumours, Cell Microbiol, 13, 1223, 10.1111/j.1462-5822.2011.01612.x · DOI
  16. Forbes, 2006, Typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro, Biotechnol Bioeng, 94, 710, 10.1002/bit.20883 · DOI · Paper page
  17. Forbes, 2007, Typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis, Cancer Res, 67, 3201, 10.1158/0008-5472.CAN-06-2618 · DOI · Paper page
  18. Rescigno, 2010, Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity, Sci Transl Med, 2, 44ra57
  19. Weiss, 2008, Containment of tumor-colonizing bacteria by host neutrophils, Cancer Res, 68, 2952, 10.1158/0008-5472.CAN-07-2984 · DOI · Paper page
  20. Seipp, 2002, Phase I study of the intravenous administration of attenuatedTyphimurium to patients with metastatic melanoma, J Clin Oncol, 20, 142, 10.1200/JCO.2002.20.1.142 · DOI · Paper page
  21. Nemunaitis, 2001, A phase I trial of genetically modifiedTyphimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer, Hum Gene Ther, 12, 1594
  22. Hoffman, 2005, Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressingTyphimurium, Proc Natl Acad Sci USA, 102, 755, 10.1073/pnas.0408422102 · DOI · Paper page
  23. Hoffman, 2007, Monotherapy with a tumor-targeting mutant ofTyphimurium cures orthotopic metastatic mouse models of human prostate cancer, Proc Natl Acad Sci USA, 104, 10170, 10.1073/pnas.0703867104 · DOI · Paper page
  24. Hoffman, 2006, Targeted therapy with aTyphimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice, Cancer Res, 66, 7647, 10.1158/0008-5472.CAN-06-0716 · DOI · Paper page
  25. Zhao, 2012, Determination of the optimal route of administration ofTyphimurium A1-R to target breast cancer in nude mice, Anticancer Res, 32, 2501
  26. Zhao, 2015, Tumor-targetingTyphimurium A1-R arrests growth of breast-cancer brain metastasis, Oncotarget, 6, 2615, 10.18632/oncotarget.2811 · DOI
  27. Hoffman, 2012, Cancer-cell killing by engineeredimaged by multiphoton tomography in live mice, Anticancer Res, 32, 4331
  28. Zhao, 2010, Vessel destruction by tumor-targetingTyphimurium A1-R is enhanced by high tumor vascularity, Cell Cycle, 9, 4518, 10.4161/cc.9.22.13744 · DOI
  29. Hoffman, 2010, Monotherapy with a tumor-targeting mutant of. Typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer, J Surg Res, 164, 248, 10.1016/j.jss.2009.02.023 · DOI
  30. Hoffman, 2009, Efficacy of a genetically-modifiedTyphimurium in an orthotopic human pancreatic cancer in nude mice, Anticancer Res, 29, 1873
  31. Bouvet, 2013, Comparison of efficacy ofTyphimurium A1-R and chemotherapy on stem-like and non-stem human pancreatic cancer cells, Cell Cycle, 12, 2774, 10.4161/cc.25872 · DOI
  32. Tanaka, 2014, Efficacy ofTyphimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX), J Cell Biochem, 115, 1254, 10.1002/jcb.24769 · DOI
  33. Tanaka, 2014, Efficacy of tumor-targetingTyphimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models, Oncotarget, 5, 12346, 10.18632/oncotarget.2641 · DOI
  34. Zhao, 2014, Efficacy of tumor-targetingTyphimurium A1-R on nude mouse models of metastatic and disseminated human ovarian cancer, J Cell Biochem, 115, 1996
  35. Hoffman, 2015, Intraperitoneal administration of tumor-targetingTyphimurium A1-R inhibits disseminated human ovarian cancer and extends survival in nude mice, Oncotarget, 6, 11369, 10.18632/oncotarget.3607 · DOI
  36. Hoffman, 2014, Tumor-targetingTyphimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy, Cell Cycle, 13, 3958, 10.4161/15384101.2014.964115 · DOI · Paper page
  37. Mori, 2015, Tumor-targetingTyphimurium A1-R in combination with trastuzumab eradicates HER-2-positive cervical cancer cells in patient-derived mouse models, PLoS ONE, 10, e0120358, 10.1371/journal.pone.0120358 · doi:10.1371/journal.pone.0120358
  38. Hoffman, 2009, Cancer metastasis directly eradicated by targeted therapy with a modifiedTyphimurium, J Cell Biochem, 106, 992, 10.1002/jcb.22078 · DOI
  39. Hoffman, 2009, Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain ofTyphimurium, Cell Cycle, 8, 870, 10.4161/cc.8.6.7891 · DOI
  40. Tsuchiya, 2014, Inhibition of spontaneous and experimental lung metastasis of soft-tissue sarcoma by tumor-targetingTyphimurium A1-R, Oncotarget, 5, 12849, 10.18632/oncotarget.2561 · DOI
  41. Hoffman, 2010, Targeted therapy of spinal cord glioma with a genetically modifiedTyphimurium, Cell Prolif, 43, 41, 10.1111/j.1365-2184.2009.00652.x · DOI
  42. Hoffman, 2012, Inhibition and eradication of human glioma with tumor-targetingTyphimurium in an orthotopic nude-mouse model, Cell Cycle, 11, 628, 10.4161/cc.11.3.19116 · DOI
  43. McClelland, 2010, High-throughput screening foravirulent mutants that retain targeting of solid tumors, Cancer Res, 70, 2165, 10.1158/0008-5472.CAN-09-4005 · DOI
  44. Zhu, 2013, A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion, Cell Rep, 5, 493, 10.1016/j.celrep.2013.09.015 · DOI
  45. Hoffman, 2016, Tumor-targetingTyphimurium A1-R: an overview, Methods Mol Biol, 1409, 1, 10.1007/978-1-4939-3515-4_1 · DOI
  46. McClelland, 2009, Analysis of pools of targeteddeletion mutants identifies novel genes affecting fitness during competitive infection in mice, PLoS Pathog, 5, e1000477, 10.1371/journal.ppat.1000477 · DOI · Paper page
  47. Bogomolnaya, 2014, Defined single-gene and multi-gene deletion mutant collections insv Typhimurium, PLoS ONE, 9, e99820, 10.1371/journal.pone.0099820 · DOI · Paper page
  48. McClelland, 2015, Analysis of two complementary single-gene deletion mutant libraries ofTyphimurium in intraperitoneal infection of BALB/c mice, Front Microbiol, 6, 1455
  49. DeAtley, 2013, Novel determinants of intestinal colonization ofserotype Typhimurium identified in bovine enteric infection, Infect Immun, 81, 4311, 10.1128/IAI.00874-13 · DOI
  50. Vila, 2013, serovar Typhimurium skills to succeed in the host: virulence and regulation, Clin Microbiol Rev, 26, 308, 10.1128/CMR.00066-12 · DOI · Paper page
  51. Hensel, 2015, Take the tube: remodelling of the endosomal system by intracellular, Cell Microbiol, 17, 639, 10.1111/cmi.12441 · DOI
  52. Forbes, 2012, Motility is critical for effective distribution and accumulation of bacteria in tumor tissue, Integr Biol, 4, 165, 10.1039/c2ib00091a · DOI
  53. Forbes, 2015, Persistent enhancement of bacterial motility increases tumor penetration, Biotechnol Bioeng, 112, 2397, 10.1002/bit.25645 · DOI · Paper page
  54. Forbes, 2015, Trg-deficientcolonize quiescent tumor regions by exclusively penetrating or proliferating, J Control Release, 199, 180, 10.1016/j.jconrel.2014.12.014 · DOI
  55. Eisenbach, 2001, Acetylation of the response regulator, CheY, is involved in bacterial chemotaxis, Mol Microbiol, 40, 731, 10.1046/j.1365-2958.2001.02425.x · DOI
  56. Blair, 1998, Electrostatic interactions between rotor and stator in the bacterial flagellar motor, Proc Natl Acad Sci USA, 95, 6436, 10.1073/pnas.95.11.6436 · DOI · Paper page
  57. Galan, 2009, serovar Typhimurium pathogenicity island 1-encoded type III secretion system translocases mediate intimate attachment to nonphagocytic cells, Infect Immun, 77, 2635, 10.1128/IAI.00077-09 · DOI · Paper page
  58. Galan, 1996, Molecular genetic bases ofentry into host cells, Mol Microbiol, 20, 263, 10.1111/j.1365-2958.1996.tb02615.x · DOI · Paper page
  59. Miller, 2008, interplay with host cells, Nat Rev Microbiol, 6, 53, 10.1038/nrmicro1788 · DOI · Paper page
  60. Bäumler, 2011, Intestinal inflammation allowsto use ethanolamine to compete with the microbiota, Proc Natl Acad Sci USA, 108, 17480, 10.1073/pnas.1107857108 · DOI · Paper page
  61. Bäumler, 2013, The dynamics of gut-associated microbial communities during inflammation, EMBO Rep, 14, 319, 10.1038/embor.2013.27 · DOI · Paper page
  62. Harshey, 2013, uses energy taxis to benefit from intestinal inflammation, PLoS Pathog, 9, e1003267, 10.1371/journal.ppat.1003267 · DOI · Paper page
  63. Bäumler, 2010, Gut inflammation provides a respiratory electron acceptor for, Nature, 467, 426, 10.1038/nature09415 · DOI · Paper page
  64. Rakoff-Nahoum, 2006, Why cancer and inflammation?, Yale J Biol Med, 79, 123
  65. Karin, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016/j.cell.2010.01.025 · DOI · Paper page
  66. Bäumler, 2014, Comparative analysis ofgenomes identifies a metabolic network for escalating growth in the inflamed gut, mBio, 5, e00929
  67. Garsin, 2010, Ethanolamine utilization in bacterial pathogens: roles and regulation, Nat Rev Microbiol, 8, 290, 10.1038/nrmicro2334 · DOI · Paper page
  68. Andrews-Polymenis, 2014, Identification of novel factors involved in modulating motility ofserotype Typhimurium, PLoS ONE, 9, e111513, 10.1371/journal.pone.0111513 · doi:10.1371/journal.pone.0111513
  69. Weiss, 2009, Tumor invasion ofserovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-α, PLoS ONE, 4, e6692, 10.1371/journal.pone.0006692 · DOI · Paper page
  70. Martin, 2011, Enterohaemorrhagicgains a competitive advantage by using ethanolamine as a nitrogen source in the bovine intestinal content, Environ Microbiol, 13, 365, 10.1111/j.1462-2920.2010.02334.x · DOI · Paper page
  71. Kendall, 2015, Ethanolamine signaling promotesniche recognition and adaptation during infection, PLoS Pathog, 11, e1005278, 10.1371/journal.ppat.1005278 · DOI
  72. al-Ramadi, 2014, -mediated tumor regression involves targeting of tumor myeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity, Cancer Immunol Immunother, 63, 587, 10.1007/s00262-014-1543-x · DOI
  73. Cao, 2014, A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity, PLoS ONE, 9, e85587, 10.1371/journal.pone.0085587 · DOI · Paper page
  74. Rowley, 2013, Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer, Cancer Immunol Res, 1, 123, 10.1158/2326-6066.CIR-13-0058 · DOI · Paper page
  75. Hoffman, 2014, Invading cancer cells are predominantly in G0/G1 resulting in chemoresistance demonstrated by real-time FUCCI imaging, Cell Cycle, 13, 953, 10.4161/cc.27818 · DOI
  76. Wanner, 2000, One-step inactivation of chromosomal genes inK-12 using PCR products, Proc Natl Acad Sci USA, 97, 6640, 10.1073/pnas.120163297 · DOI · Paper page
  77. Dudoit, 2005, Bioinformatics and computational biology solutions using R and Bioconductor, 397
  78. Olson, 2008, The RAST server: rapid annotations using subsystems technology, BMC Genomics, 9, 75, 10.1186/1471-2164-9-75 · DOI · Paper page
  79. Jin, 2012, VFDB 2012 update: toward the genetic diversity and molecular evolution of bacterial virulence factors, Nucleic Acids Res, 40, D641, 10.1093/nar/gkr989 · DOI · Paper page
  80. McClelland, 2013, Evolutionary genomics ofsubspecies, mBio, 4, e00198
  81. Bader, 2014, Enrichment Map - a Cytoscape app to visualize and explore OMICs pathway enrichment results, F1000Res, 3, 141, 10.12688/f1000research.4536.1 · DOI · Paper page

Cited by

See all 44

Metadata

Authors
Silva-Valenzuela, C. A., Desai, P. T., Molina-Quiroz, R. C., Pezoa, D., Zhang, Y., Porwollik, S., Zhao, M., Hoffman, R. M., Contreras, I., Santiviago, C. A., & McClelland, M.
Venue
Oncotarget
Published
2016-04-28
Volume
7
Issue
23
Pages
35169-35180
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2342931535
Cited by
44
References
1
FWCI
4.64
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.